网络药理学揭示熟地黄-山茱萸药对经PI3K/AKT通路防治糖尿病骨质疏松的机制
该研究采用UPLC-Q-Exactive-MS检测熟地黄-山茱萸药对的化学成分,并在链脲佐菌素诱导的1型糖尿病大鼠及高糖损伤的MC3T3-E1成骨细胞中评价其抗糖尿病骨质疏松作用,结合网络药理学预测并验证PI3K-AKT通路机制。
要点
- 熟地黄-山茱萸药对可改善1型糖尿病大鼠骨微结构和骨密度。
- 该药对通过调控PI3K-AKT信号通路促进成骨细胞分化和骨形成。
- 网络药理学提示其活性成分作用于AKT1、EGFR、TNF、MMP9、HSP90α等靶点。
核心结论
- 熟地黄-山茱萸药对通过调控PI3K-AKT信号通路抑制高糖导致的骨丢失。
研究设计与样本
- 研究采用UPLC-Q-Exactive-MS检测熟地黄-山茱萸药对化学成分。
- 链脲佐菌素诱导1型糖尿病大鼠模型,给予熟地黄-山茱萸提取物10周。
- 体外以高糖损伤MC3T3-E1成骨细胞模型评价药物作用。
- 结合网络药理学分析并在高糖损伤成骨细胞中验证机制。
主要发现
- 在熟地黄-山茱萸药对中鉴定出56种化合物。
- 该药对改善1型糖尿病大鼠骨微结构和骨密度。
- 该药对降低1型糖尿病大鼠尿脱氧吡啶啉和血清I型前胶原羧基端肽水平。
- 网络药理学识别cornuside、hydroxygenkwanin、acteoside、catalpol和echinacoside为潜在活性成分。
- 该药对通过调节PI3K-AKT信号通路促进MC3T3-E1成骨细胞分化和骨形成。
关键数值与推荐
- 网络药理学分析提示熟地黄、山茱萸及药对的作用与激素调节、炎症和代谢调控相关。
- 富集分析显示作用涉及PI3K-AKT、IL-17、TNF、MAPK和雌激素信号通路。
- 潜在活性成分与AKT1、EGFR、TNF、MMP9和HSP90α等关键节点基因相互作用。
临床怎么用
- 熟地黄-山茱萸药对可作为糖尿病骨质疏松的潜在中药干预方案。
- 其作用机制可能与调控PI3K-AKT信号通路促进骨形成有关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Diabetic osteoporosis (DOP) is a complication of diabetes characterized by reduced bone mass and increased fracture risk. Shudihuang (Rehmanniae Radix Praeparata, RR) and Shanzhuyu (Corni Fructus, CF) form a classical herb pair known as RR-CF in traditional Chinese medicine (TCM) for nourishing Yin and tonifying the kidney, and have long been used for the treatment of diabetes and OP in TCM clinical practise. However, the potential mechanism underlying the preventive and therapeutic effects of RR-CF on DOP has not been clarified. AIM OF THE STUDY: This study aimed to explore the protective effects of RR-CF on bone loss caused by diabetes and elucidate the underlying action mechanism. METHODS: The chemical constituents in RR-CF were detected using UPLC-Q-Exactive-MS. Type 1 diabetes mellitus (T1DM) was induced in rats by injecting streptozotocin, followed by administration of RR-CF extracts for 10 weeks. Bone mineral density, morphometric bone parameters, and serum and urine biochemical markers were analyzed using Micro-CT and ELISA kits. An in vitro osteoblastic injury model was constructed by subjecting MC3T3-E1 cells to high glucose and used to evaluate the effects of the RR-CF on osteoblastic bone formation. The anti-DOP mechanism of RR-CF was explored by network pharmacologic analysis and then verified in osteoblasts damaged by high glucose. RESULTS: A total of 56 compounds were identified in RR-CF. Treatment with RR-CF extracts improved the bone microstructure and mineral density in the T1DM rats, and decreased the level of urine deoxypyridinoline and serum carboxyl terminal peptide of type I procollagen. The network pharmacology analysis identified cornuside, hydroxygenkwanin, acteoside, catalpol and echinacoside as the potential active components of RR-CF against DOP by interacting with the key node genes such as AKT1, EGFR, TNF, MMP9 and HSP90α. Further GO and KEGG enrichment analysis suggested that the therapeutic effects of RR, CF and RR-CF seemed to be related to the regulation of hormones, inflammation and metabolism, as well as signaling transductions of PI3K-AKT, IL-17, TNF, MAPK and estrogen signaling pathways. RR-CF promoted osteoblast differentiation and bone formation in the MC3T3-E1 cells by regulating PI3K-AKT signaling pathway. CONCLUSION: RR-CF herb pair inhibits bone loss caused by high glucose by regulating the PI3K-AKT signaling pathways.
引用
- Hu SJ, Chen GC, Wang FY, et al. Network pharmacology analysis uncovers the mechanism of Shudihuang-Shanzhuyu herb pair in prevention and treatment of diabetic osteoporosis via PI3K/AKT pathway. J Ethnopharmacol. 2025. PMID: 40054640. doi:10.1016/j.jep.2025.119581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。